Cargando…

ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro

ONC206 (Oncoceutics) is an imipiridone with nanomolar potency and analogue of ONC201, a selective dopamine receptor D2 (DRD2) antagonist currently being investigated in phase II clinical trials for serous endometrial cancer (SEC). This study investigated the anti-proliferative efficacy of ONC206 in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yingao, Huang, Yu, Yin, Yajie, Fan, Yali, Sun, Wenchuan, Zhao, Xiaoling, Tucker, Katherine, Staley, Allison, Paraghamian, Sarah, Hawkins, Gabrielle, Prabhu, Varun, Allen, Joshua E., Zhou, Chunxiao, Bae-Jump, Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641618/ https://www.ncbi.nlm.nih.gov/pubmed/33194693 http://dx.doi.org/10.3389/fonc.2020.577141

Ejemplares similares

A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer
por: Paraghamian, Sarah E., et al.
Publicado: (2023)

MODL-06. PRECLINICAL EFFICACY OF THE IMIPRIDONE ONC-206 AGAINST MEDULLOBLASTOMA
por: Malhotra, Anshu, et al.
Publicado: (2020)

Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer
por: Fan, Yali, et al.
Publicado: (2022)

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2016)

A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells via Differential Expression of Tumorigenic Proteins
por: El-Soussi, Sarra, et al.
Publicado: (2021)

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201
por: Allen, Joshua E., et al.
Publicado: (2021)

Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer
por: Pierce, Stuart R., et al.
Publicado: (2021)

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia
por: Nii, Takenobu, et al.
Publicado: (2019)

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
por: Prabhu, Varun V., et al.
Publicado: (2017)

Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells
por: Zhang, Xin, et al.
Publicado: (2022)

Imipridone family on successful TRAIL
por: Anderson, Peter M., et al.
Publicado: (2017)

Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype
por: Hu, Wen, et al.
Publicado: (2020)

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma
por: Tu, Yong-sheng, et al.
Publicado: (2017)

Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer
por: Jackson, Amanda L., et al.
Publicado: (2017)

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

Orlistat exerts anti-obesity and anti-tumorigenic effects in a transgenic mouse model of endometrial cancer
por: Xu, Guangxu, et al.
Publicado: (2023)

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer
por: Huang, Yu, et al.
Publicado: (2023)

The Effects of NT-1044, a Novel AMPK Activator, on Endometrial Cancer Cell Proliferation, Apoptosis, Cell Stress and In Vivo Tumor Growth
por: Roque, Dario R., et al.
Publicado: (2021)

HGG-15. THE IMIPRIDONE ONC201 IN COMBINATION WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD HAS A SYNERGISTIC EFFECT IN PRECLINICAL MODELS OF PHGGS AND DMGS
por: de la Nava, Daniel, et al.
Publicado: (2021)

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
por: Arrillaga-Romany, Isabel, et al.
Publicado: (2017)

Ipatasertib exhibits anti-tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo
por: O'donnell, Jillian, et al.
Publicado: (2023)

HGG-42. PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) SHOWS ROBUST RESPONSE TO IMIPRIDONE BASED COMBINATION THERAPY
por: Borsuk, Robyn, et al.
Publicado: (2021)

Synthesis and Antiproliferative Activity of Novel Imipridone–Ferrocene Hybrids with Triazole and Alkyne Linkers
por: Czuczi, Tamás, et al.
Publicado: (2022)

Oleic Acid Exhibits Anti-Proliferative and Anti-Invasive Activities via the PTEN/AKT/mTOR Pathway in Endometrial Cancer
por: Deng, Boer, et al.
Publicado: (2023)

Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436
por: Hu, Wen, et al.
Publicado: (2021)

Malignant Brenner tumor of the ovary: Case series and review of treatment strategies
por: Zhang, Yingao, et al.
Publicado: (2019)

SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer
por: Tran, Arthur-Quan, et al.
Publicado: (2021)

Asparagus officinalis Exhibits Anti-Tumorigenic and Anti-Metastatic Effects in Ovarian Cancer
por: Xu, Guangxu, et al.
Publicado: (2021)

Genomic profiling of endometrial cancer and relationship with volume of endometrial cancer disease spread
por: Sullivan, Stephanie A., et al.
Publicado: (2021)

Tissue factor–positive extracellular vesicles in plasma are not associated with venous thromboembolism in patients with ovarian cancer
por: Hisada, Yohei, et al.
Publicado: (2023)

Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development
por: Jacques, Samuel, et al.
Publicado: (2020)

DIPG-62. PRECLINICAL EVALUATION OF IMIPRIDONE-BASED COMBINATION THERAPIES IN PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Borsuk, Robyn, et al.
Publicado: (2020)

Metastatic serous endometrial carcinoma to the ureter
por: Sahl, Jessa W., et al.
Publicado: (2021)

The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer
por: Suri, Anuj, et al.
Publicado: (2016)

A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma
por: Shimizu, Maho, et al.
Publicado: (2021)

At R206
por: CERN PhotoLab
Publicado: (1976)

Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells
por: Han, Xiaoyun, et al.
Publicado: (2015)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

Metachronous serous endometrial intraepithelial carcinoma and serous peritoneal carcinoma: analysis of probable independent lesions
por: Furuya, Mitsuko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3d0macibe47m10vjnp5grlttb0